Identification of inhibitors of ovarian cancer stem-like cells by high-throughput screening

Journal of Ovarian Research

Volumn 5, Issue 1, 2012, Pages

  Mezencev, Roman ^a   Wang, Lijuan ^a   Mcdonald, John F ^a  

^a GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Cancer stem cells; High throughput screening; Ovarian cancer

Indexed keywords

2 PHENYL 1,4 THIAZINO[3,2 C]QUINOLINE 3 THIONE; 2,3 DIBROMONAPHTHOQUINONE; 3 CYANO N,3 BIS(2 METHYLPHENYL) 2 OXOPROPANAMIDE; 3,3,4,4 TETRAMETHYLTETRAHYDRO 2,5 FURANDIOL; 5,7 DIHYDROXY 3',4' DIMETHOXYFLAVONE; AMIFOSTINE; ANTINEOPLASTIC AGENT; BLEOMYCIN; BLEOMYCIN B2; BUSULFAN; CLADRIBINE; CYTARABINE; DACARBAZINE; DACTINOMYCIN; ETHYL 2 [[[1 ADAMANTYL(METHYL)AMINO]CARBONYL]AMINO]PROPANOATE; HYDROXYUREA; MEPACRINE; MERCAPTOPURINE; METHOTREXATE; MITHRAMYCIN; MITOLACTOL; MITOTANE; N (4 CHLOROPHENYL) 1 METHYL 1H PYRAZOLO[3,4 B]QUINOLIN 5 AMINE; N' [1 (4H 1,4 BENZOTHIAZIN 2 YL)ETHYLIDENE] 2 HYDROXYBENZOHYDRAZIDE; NSC 105014; NSC 128305; NSC 14229; NSC 208913; NSC 226080; NSC 614928; NSC 616232; NSC 618332; NSC 622732; NSC 635121; NSC 636132; NSC 667467; RAPAMYCIN; STREPTOZOCIN; TAMOXIFEN; TRETAMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINBLASTINE SULFATE; VINCRISTINE; VINCRISTINE SULFATE;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER STEM CELL; CELL DIFFERENTIATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; HIGH THROUGHPUT SCREENING; HUMAN; OVARY CANCER; PRIORITY JOURNAL;

EID: 84867488416     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-5-30     Document Type: Article

References (48)

1. Cancer statistics, 2010. A Jemal, R Siegel, J Xu, E Ward, CA Cancer J Clin 2010 60 277 300 10.3322/caac.20073 20610543
2. Recurrent ovarian cancer: how important is it to treat to disease progression? TJ Herzog, Clin Cancer Res 2004 10 7439 7449 10.1158/1078-0432.CCR- 04-0683 15569973 (Pubitemid 39557505)
3. Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. SA Bapat, AM Mali, CB Koppikar, NK Kurrey, Cancer Res 2005 65 3025 3029 15833827 (Pubitemid 40524578)
4. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. S Zhang, C Balch, MW Chan, HC Lai, D Matei, JM Schilder, PS Yan, TH Huang, KP Nephew, Cancer Res 2008 68 4311 4320 10.1158/0008-5472.CAN-08-0364 18519691
5. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. T Baba, PA Convery, N Matsumura, RS Whitaker, E Kondoh, T Perry, Z Huang, RC Bentley, S Mori, S Fujii, JR Marks, A Berchuck, SK Murphy, Oncogene 2009 28 209 218 10.1038/onc.2008.374 18836486
6. Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. AB Alvero, R Chen, HH Fu, M Montagna, PE Schwartz, T Rutherford, DA Silasi, KD Steffensen, M Waldstrom, I Visintin, G Mor, Cell Cycle 2009 8 158 166 10.4161/cc.8.1.7533 19158483
7. Targeting breast cancer stem cells: fishing season open! C Ginestier, E Charafe-Jauffret, D Birnbaum, Breast Cancer Res 2010 12 312 10.1186/bcr2636 20887639
8. Targeting breast cancer stem cells. SP McDermott, MS Wicha, Mol Oncol 2010 4 404 419 10.1016/j.molonc.2010.06.005 20599450
9. Therapeutics formulated to target cancer stem cells: is it in our future? S Clayton, SA Mousa, Cancer Cell Int 2011 11 7 10.1186/1475-2867-11-7 21439058
10. Identification of selective inhibitors of cancer stem cells by high-throughput screening. PB Gupta, TT Onder, G Jiang, K Tao, C Kuperwasser, RA Weinberg, ES Lander, Cell 2009 138 645 659 10.1016/j.cell.2009.06.034 19682730
11. Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. SM Pollard, K Yoshikawa, ID Clarke, D Danovi, S Stricker, R Russell, J Bayani, R Head, M Lee, M Bernstein, JA Squire, A Smith, P Dirks, Cell Stem Cell 2009 4 568 580 10.1016/j.stem.2009.03.014 19497285
12. A molecular screening approach to identify and characterize inhibitors of glioblastoma stem cells. K Visnyei, H Onodera, R Damoiseaux, K Saigusa, S Petrosyan, D De Vries, D Ferrari, J Saxe, EH Panosyan, M Masterman-Smith, J Mottahedeh, KA Bradley, J Huang, C Sabatti, I Nakano, HI Kornblum, Mol Cancer Ther 2011 10 1818 1828 10.1158/1535-7163.MCT-11-0268 21859839
13. Isolation and characterization of stem-like cells from a human ovarian cancer cell line. L Wang, R Mezencev, NJ Bowen, LV Matyunina, JF McDonald, Mol Cell Biochem 2011 363 257 268 22160925
14. Prospective identification of tumorigenic breast cancer cells. M Al-Hajj, MS Wicha, A Benito-Hernandez, SJ Morrison, MF Clarke, Proc Natl Acad Sci USA 2003 100 3983 3988 10.1073/pnas.0530291100 12629218 (Pubitemid 36418143)
15. Identification of human brain tumour initiating cells. SK Singh, C Hawkins, ID Clarke, JA Squire, J Bayani, T Hide, RM Henkelman, MD Cusimano, PB Dirks, Nature 2004 432 396 401 10.1038/nature03128 15549107 (Pubitemid 39551674)
16. Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. V Levina, AM Marrangoni, R De Marco, E Gorelik, AE Lokshin, PLoS One 2008 3 3077 10.1371/journal.pone.0003077 18728788
17. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. C Ginestier, MH Hur, E Charafe-Jauffret, F Monville, J Dutcher, M Brown, J Jacquemier, P Viens, CG Kleer, S Liu, A Schott, D Hayes, D Birnbaum, MS Wicha, G Dontu, Cell Stem Cell 2007 1 555 567 10.1016/j.stem.2007.08.014 18371393 (Pubitemid 350056407)
18. Update on NCI in vitro drug screen utilities. SL Holbeck, Eur J Cancer 2004 40 785 793 10.1016/j.ejca.2003.11.022 15120034 (Pubitemid 38519757)
19. Mechanistic set information http://dtp.nci.nih.gov/branches/dscb/ mechanistic-explanation.html.
20. DTP basic chemical data search http://dtp.nci.nih.gov/dtpstandard/ ChemData/index.jsp.
21. AY-C Hsiao, 3D spheroid culture systems for metastatic prostate cancer dormancy studies and anti-cancer therapeutics development Universtiy of Michigan: (Doctoral dissertation). Retrieved from ProQuest Dissertations & Theses (ID 896131060) 2011
22. Kallikrein-related peptidase 7 promotes multicellular aggregation via the alpha(5)beta(1) integrin pathway and paclitaxel chemoresistance in serous epithelial ovarian carcinoma. Y Dong, OL Tan, D Loessner, C Stephens, C Walpole, GM Boyle, PG Parsons, JA Clements, Cancer Res 2010 70 2624 2633 10.1158/0008-5472.CAN-09-3415 20332224
23. Reporting data from high-throughput screening of small-molecule libraries. J Inglese, CE Shamu, RK Guy, Nat Chem Biol 2007 3 438 441 10.1038/nchembio0807-438 17637769 (Pubitemid 47080377)
24. A simple sequentially rejective multiple test procedure. S Holm, Scand J Statist 1979 6 65 70
25. Approved Oncology Drugs Set Information: A set of FDA-approved anticancer drugs to enable cancer research http://dtp.cancer.gov/branches/dscb/oncology- drugset-explanation.html.
26. DTP http://dtp.nci.nih.gov.
27. 3D MIND http://spheroid.ncifcrf.gov/spheroid/.
28. Linking pathway gene expressions to the growth inhibition response from the National Cancer Institute's anticancer screen and drug mechanism of action. R Huang, A Wallqvist, N Thanki, DG Covell, Pharmacogenomics J 2005 5 6 381 399 10.1038/sj.tpj.6500331 16103895
29. Text document with names http://dtpsearch.ncifcrf.gov/OPEN-NAMES-FEB03. TXT.
30. Hexamethylmelamine and low or moderate dose cisplatin with or without pyridoxine for treatment of advanced ovarian carcinoma: a study of the Eastern Cooperative Oncology Group. PH Wiernik, B Yeap, SE Vogl, BH Kaplan, RL Comis, G Falkson, TE Davis, E Fazzini, B Cheuvart, J Horton, Cancer Invest 1992 10 1 9 1739861
31. Changes in extranucleolar transcription during actinomycin D-induced apoptosis. A Fraschini, MG Bottone, AI Scovassi, M Denegri, MC Risueño, PS Testillano, TE Martin, M Biggiogera, C Pellicciari, Histol Histopathol 2005 20 107 117 15578429 (Pubitemid 40028989)
32. Mithramycin A sensitizes cancer cells to TRAIL-mediated apoptosis by down-regulation of XIAP gene promoter through Sp1 sites. TJ Lee, EM Jung, JT Lee, S Kim, JW Park, KS Choi, TK Kwon, Mol Cancer Ther 2006 5 2737 2746 10.1158/1535-7163.MCT-06-0426 17121920 (Pubitemid 44849000)
33. Chemotherapy of gestational choriocarcinoma. JL Lewis Jr, Cancer 1972 301517 1521
34. The clinical use of actinomycin. E Frei 3rd, Cancer Chemother Rep 1974 58 49 54 4130354
35. Mithramycin therapy in advanced testicular neoplasms. BJ Kennedy, Cancer 1970 26 755 766 10.1002/1097-0142(197010)26:4<755::AID-CNCR28202604033.0. CO;2-U 5506598
36. Mithramycin treatment of hypercalcemia. CP Perlia, NJ Gubisch, J Wolter, D Edelberg, MM Dederick, SG Taylor 3rd, Cancer 1970 25 389 394 10.1002/1097-0142(197002)25:2<389::AID-CNCR28202502173.0.CO;2-X 5413510
37. WB Pratt, RW Ruddon, WD Ensminger, J Maybaum, The anticancer drugs New York: Oxford University Press 2 1994
38. Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin. DM Gershenson, M Morris, A Cangir, JJ Kavanagh, CA Stringer, CL Edwards, EG Silva, JT Wharton, J Clin Oncol 1990 8 715 720 1690272 (Pubitemid 20127256)
39. Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors. KV Gurova, JE Hill, C Guo, A Prokvolit, LG Burdelya, E Samoylova, AV Khodyakova, R Ganapathi, M Ganapathi, ND Tararova, D Bosykh, D Lvovskiy, TR Webb, GR Stark, AV Gudkov, Proc Natl Acad Sci USA 2005 102 17448 17453 10.1073/pnas.0508888102 16287968 (Pubitemid 41740886)
40. Quinacrine has anticancer activity in breast cancer cells through inhibition of topoisomerase activity. R Preet, P Mohapatra, S Mohanty, SK Sahu, T Choudhuri, MD Wyatt, CN Kundu, Int J Cancer 2012 130 7 1660 1670 10.1002/ijc.26158 21544805
41. Quinacrine: mechanisms of antimalarial action. K Van Dyke, C Lantz, C Szustkiewicz, Science 1970 169 492 493 10.1126/science.169.3944.492 5432269
42. Chemical pleurodesis in malignant pleural effusions: a randomised prospective study of mepacrine versus bleomycin. S Koldsland, JL Svennevig, G Lehne, E Johnson, Thorax 1993 48 790 793 10.1136/thx.48.8.790 7692617 (Pubitemid 23244339)
43. Cancer stem cells and radiotherapy: new insights into tumor radioresistance. M Diehn, MF Clarke, J Natl Cancer Inst 2006 98 1755 1757 10.1093/jnci/djj505 17179471 (Pubitemid 46017927)
44. Tumour stem cells and drug resistance. M Dean, T Fojo, S Bates, Nat Rev Cancer 2005 5 275 284 10.1038/nrc1590 15803154 (Pubitemid 40488633)
45. Cancer stem cells: an old idea-a paradigm shift. MS Wicha, S Liu, G Dontu, Cancer Res 2006 66 1883 1890 10.1158/0008-5472.CAN-05-3153 16488983
46. The biology of cancer stem cells. NA Lobo, Y Shimono, D Qian, MF Clarke, Annu Rev Cell Dev Biol 2007 23 675 699 10.1146/annurev.cellbio.22.010305.104154 17645413
47. Mining the National Cancer Institute's tumor-screening database: identification of compounds with similar cellular activities. AA Rabow, RH Shoemaker, EA Sausville, DG Covell, J Med Chem 2002 45 818 840 10.1021/jm010385b 11831894 (Pubitemid 34176791)
48. The NCI60 human tumour cell line anticancer drug screen. RH Shoemaker, Nat Rev Cancer 2006 6 813 823 10.1038/nrc1951 16990858 (Pubitemid 44450469)